Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intellia Therapeutics

8.44
-0.4000-4.52%
Post-market: 8.43-0.0100-0.12%19:59 EDT
Volume:2.62M
Turnover:22.46M
Market Cap:873.69M
PE:-1.61
High:8.81
Open:8.70
Low:8.43
Close:8.84
Loading ...

NTLA's Q4 Loss Narrower Than Estimates, Revenues Increase Y/Y

Zacks
·
01 Mar

Stock Track | Intellia Therapeutics Plunges 5.8% Premarket on JPMorgan Downgrade and Competitive Concerns

Stock Track
·
28 Feb

Stock Track | Intellia Therapeutics Plunges 5% Premarket on JPMorgan Downgrade and Competitive Concerns

Stock Track
·
28 Feb

Intellia Therapeutics price target lowered to $37 from $47 at RBC Capital

TIPRANKS
·
28 Feb

Morgan Stanley Keeps Their Hold Rating on Intellia Therapeutics (NTLA)

TIPRANKS
·
28 Feb

Intellia Therapeutics Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
28 Feb

JPMorgan Downgrades Intellia Therapeutics to Neutral, Price Target is $13

MT Newswires Live
·
28 Feb

Intellia Therapeutics Cut to Neutral From Overweight by JP Morgan

Dow Jones
·
28 Feb

Wells Fargo Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)

TIPRANKS
·
28 Feb

Barclays Sticks to Their Buy Rating for Intellia Therapeutics (NTLA)

TIPRANKS
·
28 Feb

Intellia Therapeutics Inc (NTLA) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...

GuruFocus.com
·
28 Feb

U.S. RESEARCH ROUNDUP-Autodesk, Coca-Cola, NetApp

Reuters
·
28 Feb

Q4 2024 Intellia Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
28 Feb

Intellia Therapeutics: Hold Rating Amid Long-Term Prospects and Strategic Restructuring

TIPRANKS
·
28 Feb

Intellia Therapeutics Inc : JP Morgan Cuts to Neutral From Overweight; Cuts Target Price to $13 From $45

THOMSON REUTERS
·
28 Feb

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA) and Cullinan Management (CGEM)

TIPRANKS
·
28 Feb

Intellia Therapeutics price target raised to $14 from $12 at Citi

TIPRANKS
·
28 Feb

Analysts Offer Insights on Healthcare Companies: Ironwood Pharma (IRWD) and Intellia Therapeutics (NTLA)

TIPRANKS
·
28 Feb

William Blair Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)

TIPRANKS
·
28 Feb

BUZZ-Intellia Therapeutics jumps on better-than-expected Q4 collaboration revenue

Reuters
·
28 Feb